Journal Scans
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Pazopanib Is Active in Advanced Kidney Cancer
CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, CH Barrios, P Salman, OA Gladkov, A Kavina, JJ Zarbá, M Chen, L McCann, L Pandite, DF Roychowdhury, RE Hawkins
20100025
2010 Jan 25
J Clin Oncol
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
J Clin Oncol. 2010 Jan 25;[Epub Ahead of Print], CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, CH Barrios, P Salman, OA Gladkov, A Kavina, JJ Zarbá, M Chen, L McCann, L Pandite, DF Roychowdhury, RE Hawkins
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Pazopanib is a multikinase inhibitor that targets vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. Phase I/II studies of pazopanib in patients with renal cell carcinoma (RCC) have shown promising results. In this randomized, phase III trial (VEG105192), Sternberg et al investigated the efficacy and safety of pazopanib in treatment-naive and cytokine-treated patients with advanced disease. Between April 2006 and April 2007, the study enrolled 435 patients...
